Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults

Vaccine

Volumn 20, Issue 3-4, 2001, Pages 545-553

  Feikin, Daniel R ^a   Elie, Cheryl M ^a   Goetz, Matthew B ^b   Lennox, Jeffrey L ^c   Carlone, George M ^a   Romero Steiner, Sandra ^a   Holder, Patricia F ^a   O'Brien, William A ^d   Whitney, Cynthia G ^a   Butler, Jay C ^a   Breiman, Robert F ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Conjugate vaccines; HIV; Pneumococcal disease

Indexed keywords

CD4 ANTIGEN; PLACEBO; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOASSAY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; VACCINATION; VIRUS LOAD;

ADULT; ANTIBODIES, BACTERIAL; CD4 LYMPHOCYTE COUNT; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HUMANS; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE; VIRAL LOAD;

EID: 0035851352     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00347-4     Document Type: Article

References (33)

1. Pneumococcal disease during HIV infection: Epidemiologic, clinical and immunologic perspectives
2. The role of human immunodeficiency virus in pneumococcal bacteremia in San Francisco residents
3. Antibody responses in HIV infection
4. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex
5. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine
6. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine
7. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
8. 1997 USPHS/IDSA Guidelines for prevention of opportunistic infections in persons infected with human immunodeficiency virus
9. Antibody responses to Haemophilus influenzae type b vaccines in men with human immunodeficiency virus infection
10. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial
11. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study
12. Pneumococcal type 22F polysaccharide absorption improves the specificity of pneumococcal polysaccharide enzyme-linked immunosorbent assay
13. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum lot 89-S
14. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells
15. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity
16. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines
17. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae
18. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults
19. Pneumococcal capsular polysaccharide preparations may contain non-c-polysaccharide contaminants that are immunogenic
20. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children
21. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults
22. Immune function and vaccine responses in healthy advanced elderly patients
23. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults
24. Failure to elicit functional antibody response to pneumococcal vaccine in HIV-infected adults
25. Antibody response to Haemophilus influenzae type b vaccine in relation to the number of CD4 T lymphocytes in adults infected with human immunodeficiency virus
26. Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease
27. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine
28. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients
29. Pneumococcal disease among HIV-infected persons: Incidence, risk factors, and impact of vaccination
30. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients
31. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: Double-blind, randomised and placebo controlled trial
32. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I